Post-bone metastasis survival and performance status in lung cancer patients with bone metastasis

Abstract

Abstract Lung cancer is one of the most frequent primary origins to develop bone metastases that deteriorate physical function and quality of life. Antitumor agents, including molecular-targeted drugs and immune checkpoint inhibitors, have been developed in the past few decades, causing longer overall survival (OS). However, the effects of these drugs on the physical function of patients with lung cancer with bone metastases remain unclear. Herein, we investigated the factors involved in post-bone metastasis survival and performance status (PS) in such patients. The result revealed that the best PS after bone metastasis was an independent significant factor for post-bone metastasis survival. Moreover, the best overall response (BOR) of the first line after bone metastasis (post-bone mets first BOR) was significantly related to PS improvement in patients with PS 2 or poorer. Additionally, molecular target drug for driver molecular alterations was significantly involved in partial response (PR) or stable disease (SD) of post-bone mets first BOR. Conclusively, an effect of drug-induced antitumor response was significantly associated with PS as well as post-bone metastasis survival. Managing bone metastases by antitumor pharmacotherapy, particularly molecular-targeted drugs, is crucial for better physical function and survival in patients with lung cancer with bone metastases.